

Appendix

Ancillary biomarker study

Our NHMRC trial is exploring the effectiveness of judicious use of retrospective continuous glucose monitoring (r-CGM) measuring interstitial fluid glucose in achieving glycaemic targets in adults with T2D, potentially shaping primary care clinical practice, with significant impact on health and healthcare costs.

We are collecting and storing, with full ethics approval, blood samples from all consenting participants at baseline and study end, one year later. Our plan is to undertake an ancillary exploratory study of the association of epigenetic microRNA biomarkers with detailed glycaemic variability data and complications in OSMOTIC participants.